Edico Genome

edicogenome.com

Based in San Diego and founded in 2013, Edico Genome Inc. develops cutting edge solutions that power the genomic revolution. Our vision is to revolutionize genome sequencing analysis by providing unprecedented speed, scale and accuracy. The “Big Data” Problem: As DNA sequencing costs have plummeted over the last few years, furthered by Illumina’s recent announcement of the ability to sequence genomes for below $1,000, raw data generated by sequencing has increased exponentially, measuring petabytes of data, making analyses and transfer of all this data difficult. These large amounts of data produce a critical bottleneck in the DNA sequencing workflow that has previously only been addressable by throwing increasing numbers of ever more powerful CPU cores at the problem. However, since the data being produced by sequencing already far outpaces Moore’s Law, this solution has very limited sustainability.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

news image

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More

KD PHARMA GROUP AND HERBOLEA BIOTECH SIGN LICENSING AGREEMENT FOR USE OF BIO-HERBOLYSIS™ EXTRACTION TECHNOLOGY

KD Pharma Group | June 24, 2020

news image

The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe.Bio-Herbolysis™ is a highly scalable, solven...

Read More

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

news image

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More

INDUSTRIAL IMPACT

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

news image

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More
news image

CELL AND GENE THERAPY

TEVARD BIOSCIENCES AND ZOGENIX COLLABORATES TO IDENTIFY AND DEVELOP NOVEL TRNA-BASED GENE THERAPIES FOR DRAVET SYNDROME AND OTHER GENETIC EPILEPSIES

Tevard Biosciences | December 04, 2020

Tevard Biosciences, a privately-held biotechnology organization pioneering tRNA-based gene therapies, and Zogenix, a worldwide biopharmaceutical organization creating and commercializing uncommon infection treatments, today reported that the organizations have gone into a cooperation to recognize and create novel tRNA-based quality treatments for Dravet syndrome and other genetic epilepsies. Under the collaboration, Tevard will use its two interesting tRNA-based discovery platform...

Read More
news image

KD PHARMA GROUP AND HERBOLEA BIOTECH SIGN LICENSING AGREEMENT FOR USE OF BIO-HERBOLYSIS™ EXTRACTION TECHNOLOGY

KD Pharma Group | June 24, 2020

The KD Pharma Group SA ("KD Pharma"), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl ("Herbolea"), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma the rights to utilize Herbolea's Bio-Herbolysis™ extraction technology in Europe.Bio-Herbolysis™ is a highly scalable, solven...

Read More
news image

KYTOPEN PARTNERS WITH CAMBRIDGE CONSULTANTS ON FLOWFECT

Genetic Engineering and Biotechnology News | January 28, 2020

MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen....

Read More
news image

INDUSTRIAL IMPACT

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More